{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:35:39Z","timestamp":1764700539526},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T00:00:00Z","timestamp":1437868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s12288-015-0575-5","type":"journal-article","created":{"date-parts":[[2015,7,25]],"date-time":"2015-07-25T04:31:42Z","timestamp":1437798702000},"page":"3-9","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multiple Myeloma: Treatment is Getting Individualized"],"prefix":"10.1007","volume":"32","author":[{"given":"M. B.","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,26]]},"reference":[{"issue":"5","key":"575_CR1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516\u20132520","journal-title":"Blood"},{"issue":"12","key":"575_CR2","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","volume":"84","author":"SK Kumar","year":"2009","unstructured":"Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al (2009) Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc 84(12):1095\u20131110","journal-title":"Mayo Clin Proc"},{"key":"575_CR3","unstructured":"Ghalaut PS, Chaudhuri S, Singh R (2013) Recent advances in diagnosis and management of multiple myeloma: an update. In: The Association of Physicians of India, Medicine Update 2013, Section\u00a010 Hematology, Chapter 80, pp 360\u2013365"},{"key":"575_CR4","unstructured":"Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al (2007) SEER Cancer Statistics Review, 1975\u20132004. National Cancer Institute, Bethesda [online]. Available from http:\/\/seer.cancer.gov\/csr\/1975_2004\/ . Accessed Nov 2012"},{"key":"575_CR5","volume-title":"Two year report of the population based cancer registries 1999\u20132000","author":"National Cancer Registry Programme","year":"2005","unstructured":"Programme National Cancer Registry (2005) Two year report of the population based cancer registries 1999\u20132000. Indian Council of Medical Research, New Delhi"},{"issue":"4","key":"575_CR6","first-page":"210","volume":"23","author":"L Kumar","year":"2010","unstructured":"Kumar L, Verma R, Radhakrishnan VR (2010) Recent advances in the management of multiple myeloma. Natl Med J India 23(4):210\u2013218","journal-title":"Natl Med J India"},{"key":"575_CR7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","volume":"33","author":"R Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86\u201389","journal-title":"Am J Hematol"},{"key":"575_CR8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bjc.1988.243","volume":"58","author":"GV Forgeson","year":"1988","unstructured":"Forgeson GV, Selby P, Lakhani S, Zulian G, Viner C, Maitland J et al (1988) Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer 58:469\u2013473","journal-title":"Br J Cancer"},{"key":"575_CR9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842\u2013854","journal-title":"Cancer"},{"key":"575_CR10","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, Miguel JS, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412\u20133420","journal-title":"J Clin Oncol"},{"issue":"18","key":"575_CR11","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","volume":"117","author":"NC Munshi","year":"2011","unstructured":"Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B et al (2011) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117(18):4696\u20134700","journal-title":"Blood"},{"key":"575_CR12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.hoc.2014.06.007","volume":"28","author":"WCJ Niels","year":"2014","unstructured":"Niels WCJ, Donk VD, Sonneveld P (2014) Diagnosis and risk stratification in multiple myeloma. Hematol Oncol Clin N Am 28:791\u2013813","journal-title":"Hematol Oncol Clin N Am"},{"issue":"5","key":"575_CR13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1053\/j.seminoncol.2013.08.001","volume":"40","author":"S Girnius","year":"2013","unstructured":"Girnius S, Munshi NC (2013) Individualized therapy in multiple myeloma: are we there? Semin Oncol 40(5):567\u2013576","journal-title":"Semin Oncol"},{"key":"575_CR14","first-page":"2109","volume":"9","author":"M Flactif","year":"1995","unstructured":"Flactif M, Zandecki M, La\u00ef JL, Bernardi F, Obein V, Bauters F et al (1995) Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia 9:2109\u20132114","journal-title":"Leukemia"},{"key":"575_CR15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S et al (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28:269\u2013277","journal-title":"Leukemia"},{"issue":"8","key":"575_CR16","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"FM Ross","year":"2012","unstructured":"Ross FM, vet-Loiseau H, Ameye G, Guti\u00e9rrez NC, Liebisch P, O\u2019Connor S et al (2012) Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97(8):1272\u20131277","journal-title":"Haematologica"},{"key":"575_CR17","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","volume":"27","author":"H Avet-Loiseau","year":"2009","unstructured":"Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL et al (2009) Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 27:4585\u20134590","journal-title":"J Clin Oncol"},{"issue":"14","key":"575_CR18","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"16","author":"A Broyl","year":"2010","unstructured":"Broyl A, Hose D, Lokhorst H, Knegt Y, Peeters J, Jauch A et al (2010) Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 16(14):2543\u20132553","journal-title":"Blood"},{"key":"575_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1745-6150-6-23","volume":"6","author":"J Chi","year":"2011","unstructured":"Chi J, Ballabio E, Chen X, Ku\u0161ec R, Taylor S, Hay D et al (2011) MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 6:23","journal-title":"Biol Direct"},{"key":"575_CR20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","volume":"30","author":"KC Anderson","year":"2012","unstructured":"Anderson KC (2012) The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 30:445\u2013452","journal-title":"J Clin Oncol"},{"key":"575_CR21","author":"NC Munshi","year":"2013","unstructured":"Munshi NC, Anderson KC (2013) New strategies in the treatment of multiple myeloma. Clin Cancer Res. doi: 10.1158\/1078-0432.CCR-12-1881","journal-title":"Clin Cancer Res"},{"issue":"1","key":"575_CR22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3816\/CLML.2011.n.005","volume":"11","author":"J Blad\u00e9","year":"2011","unstructured":"Blad\u00e9 J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A et al (2011) Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk 11(1):44\u201349","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"575_CR23","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","volume":"27","author":"MQ Lacy","year":"2009","unstructured":"Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S et al (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27:5008\u20135014","journal-title":"J Clin Oncol"},{"issue":"12","key":"575_CR24","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","volume":"118","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Gahrton G, Bergsagel PL (2011) Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 118(12):3205\u20133211","journal-title":"Blood"},{"key":"575_CR25","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","volume":"30","author":"S Lonial","year":"2012","unstructured":"Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A et al (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30:1953\u20131959","journal-title":"J Clin Oncol"},{"key":"575_CR26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","volume":"12","author":"S Mailankody","year":"2015","unstructured":"Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M et al (2015) Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 12:286\u2013295. doi: 10.1038\/nrclinonc.2014.239","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"575_CR27","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","volume":"28","author":"M Ladetto","year":"2010","unstructured":"Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28(12):2077\u20132084","journal-title":"J Clin Oncol"},{"issue":"20","key":"575_CR28","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2013.49.2124","volume":"31","author":"NC Munshi","year":"2013","unstructured":"Munshi NC, Anderson KC (2013) Minimal residual disease in multiple myeloma. J Clin Oncol 31(20):2523\u20132526","journal-title":"J Clin Oncol"},{"issue":"20","key":"575_CR29","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonz\u00e1lez M, Barrio S, Ayala R et al (2014) Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123(20):3073\u20133079","journal-title":"Blood"},{"key":"575_CR30","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","volume":"25","author":"R Walker","year":"2007","unstructured":"Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr et al (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 25:1121\u20131128","journal-title":"J Clin Oncol"},{"key":"575_CR31","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TLY, Shaughnessy JD Jr, van Rhee F, Anaissie E et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114:2068\u20132076","journal-title":"Blood"},{"key":"575_CR32","doi-asserted-by":"crossref","unstructured":"Puente PDL, Muz B, Azab F, Luderer M, Azab AK (2014) Molecularly targeted therapies in multiple myeloma. Hindawi Publishing Corporation Leukemia Research and Treatment, Article ID 976567. doi: 10.1155\/2014\/976567","DOI":"10.1155\/2014\/976567"},{"key":"575_CR33","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1038\/bcj.2014.29","volume":"4","author":"K Dimopoulos","year":"2014","unstructured":"Dimopoulos K, Gimsing P, Gronbaek K (2014) The role of epigenetics in the biology of multiple myeloma. Blood Cancer Journal 4:e207","journal-title":"Blood Cancer Journal"},{"key":"575_CR34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1073\/pnas.2536759100","volume":"101","author":"CS Mitsiades","year":"2004","unstructured":"Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540\u2013545","journal-title":"Proc Natl Acad Sci USA"},{"key":"575_CR35","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.leukres.2010.04.001","volume":"34","author":"S Jagannath","year":"2010","unstructured":"Jagannath S, Dimopoulos MA, Lonial S (2010) Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed\/refractory multiple myeloma. Leuk Res 34:1111\u20131118","journal-title":"Leuk Res"},{"key":"575_CR36","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood-2006-07-037671","volume":"109","author":"Y Shi","year":"2007","unstructured":"Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L et al (2007) Targeting aurora kinases as therapy in multiple myeloma. Blood 109:3915\u20133921","journal-title":"Blood"},{"key":"575_CR37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2141.2007.06714.x","volume":"138","author":"T Hideshima","year":"2007","unstructured":"Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C et al (2007) Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 138:783\u2013791","journal-title":"Br J Haematol"},{"issue":"4","key":"575_CR38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/2040620711410097","volume":"2","author":"SA Khan","year":"2011","unstructured":"Khan SA, Cohen AD (2011) Experimental approaches in the treatment of multiple myeloma. Ther Adv Hematol 2(4):213\u2013230","journal-title":"Ther Adv Hematol"},{"key":"575_CR39","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3109\/10428194.2011.600481","volume":"52","author":"D Siegel","year":"2011","unstructured":"Siegel D, Jagannath S, Vesole DH, Borello I, Mazumder A, Mitsiades C et al (2011) A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma 52:2308\u20132315","journal-title":"Leuk Lymphoma"},{"key":"575_CR40","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.2010.08264.x","volume":"150","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M et al (2010) Tanespimycin with bortezomib: activity in relapsed\/refractory patients with multiple myeloma. Br J Haematol 150:428\u2013437","journal-title":"Br J Haematol"},{"key":"575_CR41","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","volume":"13","author":"P Neri","year":"2007","unstructured":"Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S et al (2007) Neutralizing B cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 13:5903\u20135909","journal-title":"Clin Cancer Res"},{"key":"575_CR42","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","volume":"66","author":"YT Tai","year":"2006","unstructured":"Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L et al (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66:6675\u20136682","journal-title":"Cancer Res"},{"key":"575_CR43","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2010-08-304022","volume":"117","author":"YX Zhu","year":"2011","unstructured":"Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA et al (2011) RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 117:3847\u20133857","journal-title":"Blood"},{"key":"575_CR44","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc952","volume":"2","author":"T Hideshima","year":"2002","unstructured":"Hideshima T, Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2:927\u2013937","journal-title":"Nat Rev Cancer"},{"key":"575_CR45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2012.10.008","volume":"19","author":"N Kroger","year":"2013","unstructured":"Kroger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H et al (2013) Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogenic tandem transplantation in multiple myeloma. Biol Blood Marrow Transpl 19:398\u2013404","journal-title":"Biol Blood Marrow Transpl"},{"key":"575_CR46","first-page":"23","volume":"8","author":"D Sugumar","year":"2015","unstructured":"Sugumar D, Keller J, Vij R (2015) Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmgenomics Pers Med 8:23\u201333","journal-title":"Pharmgenomics Pers Med"},{"key":"575_CR47","unstructured":"Fouquet G, Bories C, Guidez S, Renaud L, Herbaux C, Javed S et al (2014) Expert reviews pomalidomide for multiple myeloma. Expert Rev Hematol. Early online, 1\u201313 (2014). Available from: http:\/\/szpiczak.org\/lang\/aktualnosci\/komunikaty\/pdf\/rok_2014\/17474086_2014_966074.pdf"},{"key":"575_CR48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/asheducation-2014.1.255","volume":"1","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Laubach JP, Munshi NC, Anderson KC (2014) Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematol Am Soc Hematol Educ Progr 1:255\u2013261","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"1","key":"575_CR49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25(1):91\u2013101","journal-title":"Cancer Cell"},{"key":"575_CR50","doi-asserted-by":"crossref","unstructured":"Xie Z, Chng WJ (2014) MMSET: role and therapeutic opportunities in multiple myeloma. BioMed Res Int, Article ID 636514","DOI":"10.1155\/2014\/636514"},{"issue":"1","key":"575_CR51","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1517\/14712598.2013.807338","volume":"13","author":"G Misso","year":"2013","unstructured":"Misso G, Zappavigna S, Castellano M, Rosa GD, Martino MT, Tagliaferri P (2013) Emerging pathways as individualized therapeutic target of multiple myeloma. Expert Opin Biol Ther 13(1):S95\u2013S109","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"575_CR52","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2010.175","volume":"24","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M et al (2010) Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 24(10):1769\u20131778","journal-title":"Leukemia"},{"key":"575_CR53","author":"H Nahi","year":"2010","unstructured":"Nahi H, Sutlu T, Jansson M, Alici E, Gahrton G (2010) Clinical impact of chromosomal aberrations in multiple myeloma. J Intern Med. doi: 10.1111\/j.1365-2796.2010.02324.x","journal-title":"J Intern Med"},{"issue":"7","key":"575_CR54","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","volume":"98","author":"NV Smadja","year":"2001","unstructured":"Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98(7):2229\u20132238","journal-title":"Blood"},{"key":"575_CR55","first-page":"354","volume":"1","author":"SV Rajkumar","year":"2012","unstructured":"Rajkumar SV (2012) Doublets, triplets or quadruplets on novel agents in the treatment of newly diagnosed myeloma. ASH Educ Book 1:354\u2013361. doi: 10.1182\/asheducation-2012.1.354","journal-title":"ASH Educ Book"},{"key":"575_CR56","author":"C Scheid","year":"2015","unstructured":"Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P et al (2015) Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol. doi: 10.1111\/ejh.12491","journal-title":"Eur J Haematol"},{"key":"575_CR57","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/bcj.2013.1","volume":"3","author":"CC Leow","year":"2013","unstructured":"Leow CC, Gerondakis S, Spencer A (2013) MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J 3:e105. doi: 10.1038\/bcj.2013.1","journal-title":"Blood Cancer J"},{"key":"575_CR58","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1038\/bcj.2013.67","volume":"4","author":"NI Herath","year":"2014","unstructured":"Herath NI, Rocques N, Garancher Eych\u00e8ne A, Pouponnot C (2014) GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. Blood Cancer J 4:e175. doi: 10.1038\/bcj.2013.67","journal-title":"Blood Cancer J"},{"issue":"8","key":"575_CR59","first-page":"489","volume":"11","author":"N Biran","year":"2013","unstructured":"Biran N, Jagannath S, Chari A (2013) Risk stratification in multiple myeloma, part 1: characterization of high-risk disease. Clin Adv Hematol Oncol 11(8):489\u2013503","journal-title":"Clin Adv Hematol Oncol"},{"key":"575_CR60","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandemstem-cell transplantation. Blood 108:1724\u20131732","journal-title":"Blood"},{"issue":"Suppl 1","key":"575_CR61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330512331390140","volume":"10","author":"J Shaughnessy","year":"2005","unstructured":"Shaughnessy J (2005) Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10(Suppl 1):117\u2013126","journal-title":"Hematology"},{"issue":"11","key":"575_CR62","first-page":"4051","volume":"7","author":"W Yu","year":"2014","unstructured":"Yu W, Li J, Chen L (2014) Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis. Int J Clin Exp Med 7(11):4051\u20134062","journal-title":"Int J Clin Exp Med"},{"issue":"17","key":"575_CR63","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","volume":"118","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV et al (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118(17):4519\u20134529","journal-title":"Blood"},{"issue":"5","key":"575_CR64","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1080\/10428190801930506","volume":"49","author":"M Roussou","year":"2008","unstructured":"Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C et al (2008) Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 49(5):890\u2013895","journal-title":"Leuk Lymphoma"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-015-0575-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12288-015-0575-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-015-0575-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T05:29:05Z","timestamp":1717997345000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12288-015-0575-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,26]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1007\/s12288-015-0575-5","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,26]]}}}